in islet transplantation
Allotransplantation for patients with T1DM
An Open-Label Study to Evaluate the Safety,
Tolerability and Efficacy of Transplanted Islets and
AT-1501 Immunomodulation in Adults with Brittle Type 1
Funded by Eledon
To Our Dear Patients,
I am writing to let you know about an opportunity to participate in a research study designed for patients with "brittle" form of Type 1 Diabetes.
This study is being conducted by myself, Dr. John Fung with help of Dr.. Piotr Witkowski at the University of Chicago. This research study will assess the safety, tolerability of new medication AT-1501 used to protect islets from immunologic rejection after transplantation.
You may be eligible for this study if:
you are between the ages of 18-65,
have been diagnosed with Type 1 Diabetes for longer than 5 years,
suffer from sudden and unpredictable drops of blood glucose leading to confusion or passing out despite the best medical treatment of insulin under the guidance of an experienced diabetologist.
If you are interested in learning more about the study, please contact our Research Manager Lindsay Basto, RN, MSN, Lindsay.Basto@uchospitals.edu or call 773-702-2504 for additional information.
It is important to know that this letter is not to tell you to join the study.
It is your decision, and your participation is voluntary.
Whether you show interest, and participate in the study or not, it will have no effect on your treatment with your doctors. We would also like to let you know that Dr. Witkowski has a relationship with the study sponsor, Eledon since he received financial compensation from the sponsor for designing this protocol. .
Thank you for your interest and consideration,
John Fung MD PhD